MutualDTA: An Interpretable Drug–Target Affinity Prediction Model Leveraging Pretrained Models and Mutual Attention

Efficient and accurate drug-target affinity (DTA) prediction can significantly accelerate the drug development process. Recently, deep learning models have been widely applied to DTA prediction and have achieved notable success. However, existing methods often encounter several common issues: first, the data representations lack sufficient information; second, the extracted features are not comprehensive; and third, most methods lack interpretability when modeling drug-target binding. To overcome the above-mentioned problems, we propose an interpretable deep learning model called MutualDTA for predicting DTA. MutualDTA leverages the power of pretrained models to obtain accurate representations of drugs and targets. It also employs well-designed modules to extract hidden features from these representations. Furthermore, the interpretability of MutualDTA is realized by the Mutual-Attention module, which (i) establishes relationships between drugs and proteins from the perspective of intermolecular interactions between drug atoms and protein amino acid residues and (ii) allows MutualDTA to capture the binding sites based on attention scores. The test results on two benchmark data sets show that MutualDTA achieves the best performance compared to the 12 state-of-the-art models. Attention visualization experiments show that MutualDTA can capture partial interaction sites, which not only helps drug developers reduce the search space for binding sites, but also demonstrates the interpretability of MutualDTA. Finally, the trained MutualDTA is applied to screen high-affinity drug screens targeting Alzheimer's disease (AD)-related proteins, and the screened drugs are partially present in the anti-AD drug library. These results demonstrate the reliability of MutualDTA in drug development.